In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK partners with Pentraxin on amyloidosis treatment

Executive Summary

GlaxoSmithKline and private UK biotech Pentraxin Therapeutics (spun off from University College London) have agreed to collaborate on the latter's preclinical small molecule/antibody combination for amyloidosis, a protein misfolding disorder in which amyloid accumulates in organs and tissues such as the heart, kidneys, liver, spleen, nervous system, and GI tract.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies